Pacific Biosciences Reports Q3 2025 Financial Results with Revenue Decline and Increased Net Loss

Pacific Biosciences of California, Inc. (PacBio) reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a total revenue of $38.4 million for the quarter, a decrease of 4% from $40.0 million in the same period last year. For the nine-month period, total revenue increased slightly to $115.4 million from $114.8 million in 2024. The company experienced a decline in product revenue, which fell to $32.6 million from $35.3 million year-over-year, while service and other revenue rose to $5.8 million, up from $4.7 million. Gross profit for the quarter was $15.9 million, a significant increase from $10.0 million in the prior year, driven by lower costs of revenue.

In terms of operational performance, PacBio's total operating expenses for the nine months ended September 30, 2025, surged to $541.9 million, compared to $348.5 million in the same period of 2024. This increase was largely attributed to restructuring-related costs, including $359.3 million in accelerated amortization of acquired intangibles and $15.0 million in impairment charges. The company reported a net loss of $38.0 million for the third quarter, a 37% improvement from a net loss of $60.7 million in the same quarter of 2024. For the nine-month period, the net loss widened to $506.0 million from $312.2 million in the previous year.

PacBio's balance sheet as of September 30, 2025, showed total assets of $803.2 million, a significant decrease from $1.3 billion at the end of 2024. The decline was primarily due to a reduction in investments and intangible assets. The company reported cash, cash equivalents, and short-term investments of $298.7 million, down 23% from $389.9 million at the end of the previous year. The decrease in cash reserves reflects ongoing operational losses and restructuring costs.

Strategically, PacBio is focusing on expanding its market reach through the full-scale release of its Vega benchtop platform and enhancing its Revio platform with new chemistry and application kits. The company aims to diversify its offerings and improve clinical outcomes through its sequencing technology. Despite the challenges posed by elongated sales cycles and macroeconomic factors, PacBio remains optimistic about the growth potential in the clinical sequencing market, which it believes could drive substantial revenue growth in the future.

Looking ahead, PacBio anticipates continued fluctuations in instrument revenue due to customer purchasing behavior and funding uncertainties, particularly among academic institutions. The company is committed to managing its operational costs and enhancing its product offerings to navigate these challenges effectively.